Fidelity National Financial Inc. Purchases Shares of 90,400 AbbVie Inc. $ABBV

Key Points

• Fidelity National Financial purchased 90,400 AbbVie shares worth approximately $22.75 million, making AbbVie about 0.7% of its portfolio and its sixth-largest holding. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with $3.65 in EPS and $16.99 billion in revenue, up 10.2% year over year. The company also announced a $1.73 quarterly dividend, equivalent to a 2.7% annual yield.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $275.95, but AbbVie’s elevated valuation and proximity to its 52-week high may increase downside risk if pipeline or regulatory developments disappoint.

Fidelity National Financial Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 90,400 shares of the company's stock, valued at approximately $22,748,000. AbbVie makes up about 0.7% of Fidelity National Financial Inc.'s holdings, making the stock its 6th largest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at about $28,000. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares during the period. Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $31,000. Finally, Abound Financial LLC acquired a new stake in AbbVie in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $256.08 on Friday. The business has a 50-day moving average of $252.66 and a 200 day moving average of $228.87. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The stock has a market capitalization of $452.44 billion, a price-to-earnings ratio of 72.34, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The company's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio (DPR) is 195.48%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Royal Bank Of Canada upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, July 10th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Finally, HSBC restated a "buy" rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source